Figure 6. Levobupivacaine inhibits NSCLC progression by targeting p53. (A–D) The A549 and A427 cells were treated with levobupivacaine, or co-treated with levobupivacaine and p53 shRNA. (A and B) The cell viability was measured by MTT assays in the cells. (C and D) The cell apoptosis was measure by flow cytometry analysis in the cells. Data are presented as mean ± SD. Statistic significant differences were indicated: **P < 0.01.